Adverse events rise

December 2008
Pharmaceutical Representative;Dec2008, Vol. 38 Issue 12, p9
The article reports on the increasing claims of adverse effects on Chantix and Heparin drugs. According to the Institute for Safe Medication Practices (ISMP), the smoking cessation drug Chantix received several reports regarding its adverse reactions which caused serious injuries to patients. Moreover, ISMP also revealed that there are 20,745 reports of serious injuries which were submitted to U.S. Food and Drug Administration from the prescription of drugs in the U.S.


Related Articles

  • Rise in serious ADRs reported to US FDA.  // Reactions Weekly;11/1/2008, Issue 1226, p3 

    This article highlights data from the Institute for Safe Medication Practices on serious adverse drug reactions (ADR) reported to the U.S. Food and Drug Administration (FDA) in the first quarter of 2008. The agency received a total of 20,745 new reports of serious ADR including 4,824 reports of...

  • ISMP Adverse Drug Reactions. Shuster, Joel // Hospital Pharmacy;Apr2009, Vol. 44 Issue 4, p293 

    The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MEDWATCH program (800-FDA-1088). If you have reported an interesting, preventable ADR to...

  • Med errors result from risperidone/ropinirole confusion.  // Reactions Weekly;6/25/2011, Issue 1357, p2 

    The article reports that the U.S. Food & Drug Administration (FDA) Adverse Event Reporting System (AERS) and the Institute for Safe Medication Practices in June 2011 have received wrong medication errors resulting from confusion between the antipsychotic risperidone and the antiparkinsonian...

  • Adverse events on the rise.  // Pharmaceutical Representative;Oct2007, Vol. 37 Issue 10, p11 

    The article presents a study which examines the serious adverse effects of drugs conducted by researchers from the Institute for Safe Medication Practices and the Wake-Forest University School of Medicine in Winston-Salem, North Carolina. According to the study, the number of deaths due to side...

  • Clash Over Drue Approvals. Mitka, Mike // JAMA: Journal of the American Medical Association;7/9/2008, Vol. 300 Issue 2, p160 

    The article reports that U.S. Senator Chuck Grassley refuted accusations that his investigation of the U.S. Food and Drug Administration's (FDA) drug approval process would delay the arrival of effective medications to the market. Comments made by Doctor Mark Thornton, a former officer in the...

  • Doctors, consumers and adverse reactions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Reports on the reports generated by medWatch, a new Food and Drug Administration (FDA) program to encourage doctors to voluntarily report adverse effects caused by drugs and devices. Effects defined as serious; Monitoring of drugs and devices after approval as the weakest link in FDA's oversight...

  • FDA scraps adverse event definition. J. G. D. // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p30 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to abadon its proposed definition for a suspected adverse drug reaction (SADR).

  • FDA field targets ADR submissions. James G., Dickinson // Medical Marketing & Media;Oct97, Vol. 32 Issue 10, p30 

    Reports on the US Food and Drug Administration field compliance program for drug firms with a history of adverse drug reaction reporting problems. Examination of completion and accuracy of ADR submissions; Internet address of the compliance program.

  • Making a difference.  // Nature Biotechnology;Apr2009, Vol. 27 Issue 4, p297 

    This editorial states that officials at the U.S. Food and Drug Administration (FDA) should focus on producing a comprehensive database that provides information on adverse events and effects associated with various drugs. Beneath the administration of U.S. President Barack Obama, the FDA is led...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics